Merck KGaA, Sysmex Inostics Garner CE Mark for Liquid Biopsy CRC Test | GenomeWeb

This article has been updated with additional details about analysis Sysmex performed on the OncoBEAM RAS CRC test's concordance with tissue-based tests.

NEW YORK (GenomeWeb) – Merck KGaA and Sysmex Inostics have garnered a CE Mark for the OncoBEAM RAS CRC, a blood test the companies are developing and commercializing together.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

Sponsored by
Agilent Technologies

In this online seminar, speakers from the Center for Personalized Diagnostics at Penn Medicine will discuss the design and technical validation of a custom next-generation sequencing panel to detect mutations in a wide array of tumor types.